Schick delisted from Nasdaq

Article

Schick Technologies has been delisted from the Nasdaq stock exchange, the company has reported. On Sept. 15, Schick received notice from the Nasdaq Listing Qualifications Panel that as of close of business, Schick’s common stock would no longer be

Schick Technologies has been delisted from the Nasdaq stock exchange, the company has reported. On Sept. 15, Schick received notice from the Nasdaq Listing Qualifications Panel that as of close of business, Schick’s common stock would no longer be traded on the exchange. The panel attributed its decision to Schick’s inability to file its 10-K for fiscal 1999 (end-March) on time, as well as factors discussed in Schick’s 8-K, filed on Sept. 2.

Schick will request a review of the panel’s decision within the 15-day limit required by Nasdaq’s marketplace rules, and plans to file its 10-K and its 10-Q for the quarter ended June 30 as soon as the firm’s new accountants, Grant Thornton, complete their audit of Schick’s financial statements. Schick’s former accounting firm, PricewaterhouseCoopers, resigned as the company’s independent accountants on Aug. 25. Schick will seek relisting on the exchange, or apply for listing on another exchange, once its filings are current with the Securities and Exchange Commission, according to the Long Island City, NY-based company.

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.